重组人生长激素致儿童呕吐和腹痛一例
|
摘要
1例8岁患儿,诊断为"性早熟",第6次皮下注射重组人生长激素后10 min出现呕吐、腹痛,20 min后自行缓解;次日晨起诉恶心、双上肢酸痛,后自动缓解。停药后,患儿上述症状均未再出现。经分析,该患儿的呕吐和腹痛症状是由重组人生长激素药物本身或辅料苯酚的不良反应导致的。临床上如出现上述情况,应立即停药就医,及时缓解不良反应症状,并寻找治疗原疾病的替代药物。
An 8-year-old child was diagnosed as "precocious puberty". The 6 th subcutaneous injection of recombinant human growth hormone was followed by vomiting and abdominal pain for 10 min and spontaneous remission for 20 min.The next morning, the child complained of nausea and pain in both upper limbs. After withdraw of drugs, the above symptoms did not appear again. After analysis, the symptoms of vomiting and abdominal pain in the child were caused by adverse drug reactions of the recombinant human growth hormone itself or the excipient phenol. In clinical practice, in case of the above situation occurs, it is necessary to stop drugs and seek medical advice immediately, relieve the symptoms of adverse drug reaction in time, and look for alternative drugs for the original disease.
An 8-year-old child was diagnosed as "precocious puberty". The 6 th subcutaneous injection of recombinant human growth hormone was followed by vomiting and abdominal pain for 10 min and spontaneous remission for 20 min.The next morning, the child complained of nausea and pain in both upper limbs. After withdraw of drugs, the above symptoms did not appear again. After analysis, the symptoms of vomiting and abdominal pain in the child were caused by adverse drug reactions of the recombinant human growth hormone itself or the excipient phenol. In clinical practice, in case of the above situation occurs, it is necessary to stop drugs and seek medical advice immediately, relieve the symptoms of adverse drug reaction in time, and look for alternative drugs for the original disease.
引文
[1] Saenger P.Ten years of biosimilar recombinant human growth hormone in Europe[J].Drug Des Devel Ther,2017(11):1505-1507.
[2] Tanaka T,Yokoya S,Hoshino Y,et al.Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age:final report from an open and multi-center study[J].Clin Pediatr Endocrinol,2018,27(3):145-157.
[3] Bell J,Parker KL,Swinford RD,et al.Long-term safety of recom-binant human growth hormone in children[J].J Clin Endocrinol Metab,2010,95(1):167-177.
[4] Critical evaluation of the safety of recombinant human growth hormone administration:statement from the Growth Hormone Research Society[J].J Clin Endocrinol Metab,2001,86(5):1868-1670.
[5] Clayton PE,Cowell CT.Safety issues in children and adolescents during growth hormone therapy--a review[J].Growth Horm IGF Res,2000,10(6):306-317.
[6] Cinciripini GS,Donahue S,Borchert MS.Idiopathic intracranial hypertension in prepubertal pediatric patients:characteristics,treat-ment,and outcome[J].Am J Ophthalmol,1999,127(2):178-182.
[7] Saenger P.Metabolic consequences of growth hormone treatment in paediatric practice[J].Horm Res,2000(53 Suppl 1):60-69.
[8] Kang L,Dian-Chi Z,Qi-Yong W,et al.Effect of long term glucocorticoid treatment on human growth hormone secretion in chil-dren and adolescents and the safety and effectiveness of recombinant human growth hormone treatment[J].Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2011,33(1):1-4.
[9] López-Siguero J,Borrás Pérez MV,Balser S,Khan-Boluki J,et al.Long-term safety and efficacy of the recombinant human growth hormone Omnitrope? in the treatment of Spanish growth hormone deficient children:results of a phase Ⅲ study[J].Adv Ther,2011,28(10):879-893.
[2] Tanaka T,Yokoya S,Hoshino Y,et al.Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age:final report from an open and multi-center study[J].Clin Pediatr Endocrinol,2018,27(3):145-157.
[3] Bell J,Parker KL,Swinford RD,et al.Long-term safety of recom-binant human growth hormone in children[J].J Clin Endocrinol Metab,2010,95(1):167-177.
[4] Critical evaluation of the safety of recombinant human growth hormone administration:statement from the Growth Hormone Research Society[J].J Clin Endocrinol Metab,2001,86(5):1868-1670.
[5] Clayton PE,Cowell CT.Safety issues in children and adolescents during growth hormone therapy--a review[J].Growth Horm IGF Res,2000,10(6):306-317.
[6] Cinciripini GS,Donahue S,Borchert MS.Idiopathic intracranial hypertension in prepubertal pediatric patients:characteristics,treat-ment,and outcome[J].Am J Ophthalmol,1999,127(2):178-182.
[7] Saenger P.Metabolic consequences of growth hormone treatment in paediatric practice[J].Horm Res,2000(53 Suppl 1):60-69.
[8] Kang L,Dian-Chi Z,Qi-Yong W,et al.Effect of long term glucocorticoid treatment on human growth hormone secretion in chil-dren and adolescents and the safety and effectiveness of recombinant human growth hormone treatment[J].Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2011,33(1):1-4.
[9] López-Siguero J,Borrás Pérez MV,Balser S,Khan-Boluki J,et al.Long-term safety and efficacy of the recombinant human growth hormone Omnitrope? in the treatment of Spanish growth hormone deficient children:results of a phase Ⅲ study[J].Adv Ther,2011,28(10):879-893.